Month: November 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be...

Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines...

InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Completed Production of a Test Batch of its SmoothX™ Barium Sulfate CT Contrast Media Oral Suspension for the Canadian CT Imaging Market

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has completed production of a test batch...

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and...

Lumanity Announces Strategic Partnership with HealthVerity to Provide Streamlined Access to Real-World Data, World-Class Analytics, and Value Demonstration Expertise

Lumanity Announces Strategic Partnership with HealthVerity to Provide Streamlined Access to Real-World Data, World-Class Analytics, and Value Demonstration Expertise Lumanity’s...

Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

error: Content is protected !!